Cowen Remains Bullish on Spark Therapeutics (ONCE) Following Top-Line SPK-RPE65 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Strong AI earnings lift S&P 500, Nasdaq as inflation data calms rate-hike jitters
- Oil prices little changed as investors weigh lower demand against US-Iran talks deadlock
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Wall Street ends down as US-Iran peace optimism fades
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Roth Capital Raises Price Target on Spark Therapeutics (ONCE) to $90 Following Top-Line Results
October 5, 2015 11:03 AM EDTRoth Capital reiterated a Buy rating on Spark Therapeutics (NASDAQ: ONCE), and raised the price target to $90.00 (from $71.00), following the announced top-line results for the Phase 3 trial of SPKRPE65. The reported study represents the first successful controlled gene therapy trial. Spark... More
Pre-Open Stock Movers 10/05: (ONCE) (FOLD) (TWTR) Higher; (APP) (FEYE) (VRX) Lower (more...)
October 5, 2015 9:24 AM EDTSpark Therapeutics (NASDAQ: ONCE) 37.4% HIGHER; announced positive top-line results from the Phase 3 pivotal trial of its lead gene therapy product candidate, SPK-RPE65, for the treatment of RPE65-mediated inherited retinal dystrophies (IRDs). The pivotal trial met its primary endpoint (p = 0.001), demonstrating improvement of functional vision in the intervention group compared to the control group, as measured by the change in bilateral mobility testing between baseline and one year.
American Apparel, Inc. (NYSE: APP) 24% LOWER; files Chapter 11
AmicusTherapeutics... More
Spark Therapeutics (ONCE) Announces SPK-RPE65 Phase 3 Met Primary Endpoint
October 5, 2015 6:23 AM EDTSpark Therapeutics (NASDAQ: ONCE) announced positive top-line results from the Phase 3 pivotal trial of its lead gene therapy product candidate, SPK-RPE65, for the treatment of RPE65-mediated inherited retinal dystrophies (IRDs).
The pivotal trial met its primary endpoint (p = 0.001), demonstrating improvement of functional vision in the intervention group compared to the control group, as measured by the change in bilateral mobility testing between baseline and one year.
There were no serious adverse events related to SPK-RPE65 or deleterious immune responses observed in the trial.... More
